Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure

被引:9
|
作者
Dizaye, Kawa [1 ]
Ali, Rojgar H. [2 ]
机构
[1] Hawler Med Univ, Coll Med, Minara Village A05, Erbil, Iraq
[2] Hawler Med Univ, Coll Pharm, Erbil, Iraq
来源
BMC PHARMACOLOGY & TOXICOLOGY | 2019年 / 20卷 / 1期
关键词
Neprilysin; Sacubitril; Neurohumoral changes; Heart failure; Angiotensin inhibitors; ACUTE MYOCARDIAL-INFARCTION; ALISKIREN; RECEPTOR; SYSTEM; LCZ696; MMP-9; OLD;
D O I
10.1186/s40360-019-0304-z
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BackgroundThe activation of neurohumoral compensatory mechanisms is a common physiological phenomenon in heart failure in order to make up for a failing heart, which will usually have a deteriorating effect on overall health condition. Many medications, such as neprilysin and angiotensin inhibitors, have recently been introduced to remediate neurohumoral changes. This study was conducted to evaluate the efficacy of the sacubitril-aliskiren combination versus the sacubitril-ramipril combination in the treatment of neurohumoral changes in rats with experimentally induced heart failure.MethodThirty Wister rats were randomly assigned into five groups each of six rats, the first group was the control group. Intraperitoneal isoprenaline injections of 5mg/kg/day for 1week were used to induce experimental models of heart failure in rats of the rest of experimental groups. The second group served as a positive control. Rats in the third, fourth, and fifth groups received oral daily dose of sacubitril 30mg/kg/day, sacubitril-aliskiren 30,10mg/kg/day, and sacubitril-ramipril 30/10mg/kg/day respectively, for 2weeks.ResultsInduction of heart failure in rats has significantly increased circulating NT-proBNP (980116.71pg/ml), MMP9 (15.850.57ng/ml), troponin-I (3.090.147ng/ml), CK-MB (31.55 +/- 1.69ng/ml), renin (736 +/- 45.8pg/ml), urea (52.1 +/- 1.57mg/dl), and creatinine (0.92 +/- 0.04mg/dl). Significant decreases in glomerular filtration rate (7.031 +/- 1.6ml/hr./kg), urine flow (0.2761 +/- 0.06ml/h/kg), total solute excretion (0.11 +/- 0.03meq/m), and mean blood pressure (83.5 +/- 2.6mm hg) were seen in rats with heart failure. Rats treated with sacubitril combined with aliskiren or ramipril showed a statistically significant reduction of NT-proBNP, MMP9, troponin serum urea, and serum creatinine. Sacubitril-aliskiren or sacubitril-ramipril administration produced a significant increase in renin plasma level, total solute excretion, urine flow, and glomerular filtration rate.Conclusion Sacubitril in combination with aliskiren or with ramipril effectively reduced plasma cardiac biomarkers, such as CK-MB, MMP9, and NT-proBNP, in rats with heart failure. Both combinations showed significant remediation of renal function through increasing GFR, urine flow, and total solute excretion, as well as reducing plasma level of renin. Net results revealed that the sacubitril-aliskiren combination has similar remediating effects on neurohumoral changes compared to the sacubitril-ramipril combination.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure
    Kawa Dizaye
    Rojgar H. Ali
    BMC Pharmacology and Toxicology, 20
  • [2] Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure
    Vardeny, Orly
    Miller, Ryan
    Solomon, Scott D.
    JACC-HEART FAILURE, 2014, 2 (06) : 663 - 670
  • [3] Angiotensin-Neprilysin Inhibition Versus Enalapril in Heart Failure
    Lyakishev, A. A.
    KARDIOLOGIYA, 2014, 54 (12) : 47 - 48
  • [4] Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure
    Prenner, Stuart B.
    Shah, Sanjiv J.
    Yancy, Clyde W.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (08)
  • [5] Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure
    Stuart B. Prenner
    Sanjiv J. Shah
    Clyde W. Yancy
    Current Atherosclerosis Reports, 2016, 18
  • [6] Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure
    Velazquez, Eric J.
    Morrow, David A.
    DeVore, Adam D.
    Duffy, Carol I.
    Ambrosy, Andrew P.
    McCague, Kevin
    Rocha, Ricardo
    Braunwald, Eugene
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (06): : 539 - 548
  • [7] Combined angiotensin receptor and neprilysin inhibition therapy for heart failure
    Lu, Becky N.
    Davis, Lindsay E.
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2018, 31 (07): : 35 - 37
  • [8] Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure
    Mc Causland, Finnian R.
    Lefkowitz, Marty
    Claggett, Brian
    Anavekar, Nagesh
    Senni, Michele
    Gori, Mauro
    Jhund, Pardeep S.
    McGrath, Martina
    Packer, Milton
    Shi, Victor
    van Veldhuisen, Dirk
    Zannad, Faiez
    Comin-Colet, Josep
    Pfeffer, Marc A.
    McMurray, John J.
    Solomon, Scott
    CIRCULATION, 2020, 142
  • [9] Angiotensin-neprilysin inhibition versus enalapril in heart failure
    Ostios Garcia, L.
    REVISTA CLINICA ESPANOLA, 2015, 215 (01): : 55 - 56
  • [10] Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
    McMurray, John J. V.
    Packer, Milton
    Desai, Akshay S.
    Gong, Jianjian
    Lefkowitz, Martin P.
    Rizkala, Adel R.
    Rouleau, Jean L.
    Shi, Victor C.
    Solomon, Scott D.
    Swedberg, Karl
    Zile, Michael R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (11): : 993 - 1004